Finanzen von Korro Bio Inc (KRRO)KRROKorro Bio Inc

Evaluating the bottom line, Korro Bio, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -97.69%, provide a clear picture of how effectively KRRO converts its operational activities into shareholder value.

In the context of the broader market, KRRO competes directly with industry leaders such as PLX and IKT. With a market capitalization of $244.81M, it holds a leading position in the sector. When comparing efficiency, KRRO's gross margin of N/A stands against PLX's 60.99% and IKT's N/A. Such benchmarking helps identify whether Korro Bio, Inc. is trading at a premium or discount relative to its financial performance.

Korro Bio Inc has reported substantial revenue fluctuations, with a total revenue of $2,271,000 in Q4 2024, but has faced increasing net losses, culminating in a net income loss of $50,042,000 in Q4 2025. Despite these challenges, the gross margin remains at 100% for the last reported quarters, indicating strong potential for profitability once revenues stabilize.